

Table of Contents

Introduction 1

I. What Are CGMPs? 3

- A. Principles
- B. Legal Framework
- C. FDA Guidance to Industry

II How Does FDA Evaluate CGMP Compliance? 62

- A. Establishment Inspections
- B. Samples
- C. Field Alert Reports
- D. Adverse Event Reports and Consumer Complaints
- E. Risk-Based Selection of Sites and Inspection Frequency/Rigor
- F. Regulation of CGMPs for OTC Monograph and Homeopathic Drugs

III What Are the Consequences of Noncompliance? 72

- A. Advisory Actions: Warning Letters, Untitled Letters and Regulatory Meetings
- B. Import Detentions and Import Alerts
- C. Recalls
- D. Seizures
- E. Injunctions
- F. Criminal Prosecutions
- G. False Claims Act and Qui Tam Investigations
- H. Other Consequences
- I. Certificates of Export/Government Contracts
- J. Application Disapproval/Revocation
- K. Application Integrity Policy

Table of Contents, continued

IV Recent CGMP Enforcement Activity 86

A. The Pattern of Enforcement

B. GlaxoSmithKline, PLC and its Subsidiary SB Pharmco Puerto Rico Inc.

C. Genzyme Corporation

D. Ranbaxy Laboratories Limited and its Subsidiary Ranbaxy USA Inc.

V How Do We Remain “Current” with CGMPs? 89

VI The Lawyer’s Role in CGMP Counseling 92